Skip to main content
. Author manuscript; available in PMC: 2008 Jul 1.
Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2007 Aug 13;77(1):51–58. doi: 10.1016/j.plefa.2007.05.006

Fig 5.

Fig 5

Ciglitazone decreases COX-2 expression and PGE2 production in a PPARγ independent manner: Both A427 and A549 cells were transiently transfected with a dn. PPARγ construct for 24 hrs followed by the addition of ciglitazone (10 μM, 24 hrs). Expression of dn. PPARγ suppressed both basal level as well as ciglitazone induced PPRE activity in both A427 (A) and A549 cells (B). Consistent with the findings in figure 2, COX-2 ELISA assays show that IL-1β treatment significantly increases COX-2 protein expression and addition of ciglitazone significantly decreases COX-2 expression (* P < 0.05). Introduction of a dn. PPARγ [20] did not significantly change the suppressive effect of ciglitazone on COX-2 in both A427 (C) and A549 (D) cells. PGE2 is inhibited by ciglitazone treatment in both cell lines (E and F) as shown previously (* P < 0.05). Here the suppression effect of ciglitazone on PGE2 is also PPARγ expression independent as there is no significant changes in suppression of PGE2 production by ciglitazone observed in dn. PPARγ [20] expressing NSCLC cells (E and F). Data are one representative experiment out of three independent experiments.